The role of echocardiography in stroke risk assessment in patients with atrial fibrillation: Is it additive or does it simply echo clinical risk factors?

Europace

Volumn 14, Issue 1, 2012, Pages 1-2

  Pisters, Ron ^a   Olesen, Jonas B ^b   Lip, Gregory Y H ^c  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DRUG INDICATION; ECHOCARDIOGRAPHY; EDITORIAL; EUROPE; HEART ATRIUM FIBRILLATION; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SCORING SYSTEM; STROKE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

ATRIAL FIBRILLATION; ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY, TRANSESOPHAGEAL; FEMALE; HUMANS; MALE; THROMBOEMBOLISM;

EID: 84055190136     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eur310     Document Type: Editorial

References (12)

1. Lip GY. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate risk' [CHADS2 score=1]: Simplifying stroke risk assessment and thromboprophylaxis in real-life clinical practice. Thromb Haemost. 2010;103: 683-5.
2. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12: 1360-420.
3. Olesen JB, Lip GYH, Hansen ML, Hansen PR, Tolstrup JS, Lindharsen J et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. BMJ 2011;342:d124.
4. National Collaborating Centre for Chronic Conditions. Atrial Fibrillation: National Clinical Guideline for Management in Primary and Secondary Care. London: Royal College of Physicians; 2006. http://rcplondon.ac. uk/pubs/books/af/index.asp.
5. Providěncia R, Botelho A, Trigo J, Quintal A, Nascimento J, Mota P et al. Possible refinement of clinical thromboembolism assessment in patients with atrial fibrillation using echocardiographic parameters. Europace 2011;14:36-45.
6. Watson T, Shantsila E, Lip GYH. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009;373:155-66.
7. Osranek M, Bursi F, Bailey KR, Grossardt BR, Brown RD Jr, Kopecky SL et al. Left atrial volume predicts cardiovascular events in patients originally diagnosed with lone atrial fibrillation: Three-decade follow-up. Eur Heart J. 2005;26:2556-61. (Pubitemid 41679360)
8. Aronow WS, Gutstein H, Hsleh FY. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. Am J Cardiol 1989;63:366-7. (Pubitemid 19049253)
9. Oakes RS, Badger TJ, Kholmovski EG, Akoum N, Burgon NS, Blauer JJ et al. Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation. Circulation 2009;119:1758-67.
10. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel userfriendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;138:1093-100.
11. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost. 2011;106:567-752.
12. Go A, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. Circulation 2009;119:1363-69.